<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is a clinicopathologic disorder characterized by the persistent presence of anticardiolipin antibodies, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="2" ids="50249">anticoagulants</z:chebi>, or both in the plasma of patients with arterial or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> or obstetric complications </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> involved in this syndrome have a relatively weak affinity for <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding proteins such as b(2) <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I and prothrombin </plain></SENT>
<SENT sid="2" pm="."><plain>In certain conditions they form bivalent antibody-protein complexes that bind with a relatively high affinity to negatively charged <z:chebi fb="0" ids="16247">phospholipid</z:chebi> surfaces </plain></SENT>
<SENT sid="3" pm="."><plain>Evidence is accumulating for a pathogenetic role of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> via interference with surface-mediated <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and procoagulant processes </plain></SENT>
<SENT sid="4" pm="."><plain>The syndrome is characterized by the recurrence of thrombotic and obstetric complications </plain></SENT>
<SENT sid="5" pm="."><plain>Retrospective studies have suggested that patients with APS and <z:mp ids='MP_0005048'>thrombosis</z:mp> need a high-intensity <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment </plain></SENT>
<SENT sid="6" pm="."><plain>A few small prospective studies support treatment with a targeted INR of 2 to 3 </plain></SENT>
</text></document>